Skip to main content

Korro Bio, Inc.

corporate_fare Company Profile

Korro Bio, Inc.

KRRO·NASDAQ·Life Sciences·CIK 0001703647

We are a biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines that edit RNA. Our goal is to treat both rare and common diseases. We are building a portfolio of programs designed to use the body's natural RNA editing process to make a precise, temporary change to a single nucleoside (converting adenosine to inosine). By editing RNA instead of DNA, we aim to expand the scope of genetic medicines, offering greater precision and adjustability, which could lead to increased specificity and better long-term tolerability. Our approach uses oligonucleotides, and we plan to deliver our medicines to patients using our proprietary platform. This platform incorporates established delivery methods, such as N-acetylgalactosamine (GalNAc)-conjugated delivery for subcutaneous administration, along with our manufacturing expertise and the existing regulatory pathways for approved oligonucleotide medicines. However, the scientific evidence supporting the feasibility of developing lead candidates using our RNA editing technology is preliminary and limited. Regulatory bodies have not yet set definitive guidelines for the overall development of RNA editing therapies, and limited clinical data has been generated to date. The flexibility of RNA editing, combined with our OPERA platform, significantly expands the range of potential therapeutic targets. Large-scale genome sequencing has increasingly identified genetic variations that cause various human diseases, both rare and common. Genetic mutations, including single nucleotide variants (SNVs), linked to disease are diverse and can impact gene function and related biochemical pathways. Data show that SNVs can lead to either a loss-of-function or a gain-of-function of a gene. Additionally, most SNVs involved in complex diseases modulate gene function. By editing RNA to mimic an SNV, we aim to address unmet patient needs by temporarily modifying gene expression and the resulting protein function.

Korro Bio, Inc. (NASDAQ:KRRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for KRRO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Korro Bio Secures $85M Financing, Extends Runway to 2028, and Nominates New Clinical Candidate
  • Korro Bio Nominates KRRO-121 for Clinical Development in Hyperammonemia, Updates Pipeline
  • Korro Bio Secures $85M in Oversubscribed Private Placement, Extending Cash Runway into H2 2028
  • Korro Bio Secures $85M in Oversubscribed Private Placement
  • Korro Bio Highlights "Blockbuster Potential" of KRRO-121 for Ammonia Control at Analyst Day

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.39M
Net Income
-$117.26M
Diluted EPS
-$12.48
Op. Cash Flow
-$78.56M
Free Cash Flow
-$79.08M
Operating Income
-$121.86M
Cash & Equivalents
$21.82M
Debt / Equity
0.00×
Net Margin
-18.34×
Shares Outstanding
9.42M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-104156
$12.19
52-week range · as of 2026-11-05 $5.2 – $38.42
Market cap
$167.18M
Volume
123.5K (0.6× avg)
3-mo avg 213.2K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KRRO - Filings & News (Page 2)

KRRO
Mar 12, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.61
Real-time Price: $12.19 info
Change: +$1.58 (+15%) info
Market Cap: $167.178M info
KRRO
Mar 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.00
Real-time Price: $12.19 info
Change: +$1.19 (+11%) info
Market Cap: $167.178M info
KRRO
Mar 09, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.47
Real-time Price: $12.19 info
Change: -$1.28 (-9%) info
Market Cap: $167.178M info
KRRO
Mar 09, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $11.18
Real-time Price: $12.19 info
Change: +$1.01 (+9%) info
Market Cap: $167.178M info
KRRO
Jan 27, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.73
Real-time Price: $12.19 info
Change: +$1.46 (+14%) info
Market Cap: $167.178M info
KRRO
Jan 15, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.80
Real-time Price: $12.19 info
Change: +$3.39 (+39%) info
Market Cap: $167.178M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets